Contact | Print version | PDF version | Send article | RSS feed

Amorfix in-licenses novel technology to begin therapeutic program for neurodegenerative diseases

07 Feb 2006 - Amorfix Life Sciences Ltd. reported that it has obtained an exclusive worldwide license to novel targets on Superoxide Dismutase-1 (SOD1), which is a protein known to misfold and aggregate in the neurological disease Amyotrophic Lateral Sclerosis (ALS). The company also obtained an exclusive five-year option to acquire the intellectual property and know how surrounding the licensed technology. The company will use these novel targets to initiate its therapeutic program for neurodegenerative diseases, beginning with ALS.
 
The SOD1 targets were discovered by Dr. Neil Cashman, the company's Chief Scientific Officer, in his former academic laboratory at the University of Toronto, Centre for Research in Neurodegenerative Diseases. The University subsequently assigned all rights to Dr. Cashman who has licensed the technology to Amorfix.